Navigation Links
Valproic acid shown to halt vision loss in patients with retinitis pigmentosa
Date:7/21/2010

WORCESTER, MASS. Researchers at the University of Massachusetts Medical School (UMMS) believe they may have found a new treatment for retinitis pigmentosa (RP), a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.

In the July 20 online edition of the British Journal of Ophthalmology, Shalesh Kaushal, MD, PhD, chair of ophthalmology and associate professor of ophthalmology and cell biology at UMMS, and his team, describe a potential new therapeutic link between valproic acid and RP, which could have tremendous benefits for patients suffering from the disease. In a retrospective study, valproic acidapproved by the FDA to reduce seizures, treat migraines and manage bipolar disorderappeared to have an effect in halting vision loss in patients with RP and in many cases resulted in an improved field of vision. Results from this study, in conjunction with prior in vitro data, suggest valproic acid may be an effective treatment for photoreceptor loss associated with RP.

UMass Medical School will be the coordinating site for a $2.1 million, three-year clinical trial funded by the Foundation Fighting Blindness/National Neurovision Research Institute quantifying the potential of valproic acid as a treatment for RP. The clinical trials will build upon Kaushal's work in the retrospective study in which patients were treated off-label with doses of valproic acid ranging from 500mg to 750mg per day over the course of two to six months. Treated at a time when patients normally experience rapid vision loss as a result of RP, five of the seven patients in the study experienced improvement in their field of vision. '/>"/>

Contact: Jim Fessenden
james.fessenden@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Promising results shown for kidney cancer drug
2. UB specialized exercise regimen shown to relieve prolonged concussion symptoms
3. BBS proteins shown to run an export business that protects cilia
4. Carvedilol shown to have unique characteristics among beta blockers
5. Widely used virus assay shown unreliable when compared to other methods
6. Twin nanoparticle shown effective at targeting, killing breast cancer cells
7. Dictyostelium cells shown to lay breadcrumb trail as first step in multicellular formation
8. Ultrasound shown to exert remote control of brain circuits
9. High-resolution imaging expands vision research of live birds of prey
10. Vitamin deficiency after weight loss surgery can cause vision loss in newborns
11. Kids now see fewer television ads for sweets and beverages, but more for fast food
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ( ... Market Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market is estimated ... 2019. Although the U.S. market holds a larger share in ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... means that they must be continually replaced by calling ... types needed by the body. Claus Nerlov and ... unit in Monterotondo, Italy, in collaboration with researchers from ... in Sweden, have now uncovered how an intracellular communication ...
... the simplest life forms on our planet, consisting of only ... and archebacteria), viruses are the second most common type of ... form. In order to gain a better understanding of the ... would be highly useful to be able to determine their ...
... The function of horned beetles' wild protrusions has been ... plausible; combat and mate selection, more likely. Even Charles ... one imagines with some frustration -- the horns were ... (Dec. 2006) and the Nov. 2006 issue of Evolution, ...
Cached Biology News:Lost in the labyrinth 2Weighty viruses 2Vanishing beetle horns have surprise function 2Vanishing beetle horns have surprise function 3
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics ... from a new partner. STT-Systems has developed an ... years, with offerings in the optical-motion capture, 3D scanning, and ... measurement unit), iSen, is opening eyes around the world. With ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic ... ... , ... ...
... , March 11 Stem Cell Assurance, ... to announce the inclusion of one of the Cleveland Clinic,s ... F.A.C.S.  Dr. Ross will officially take up Vice Chairmanship for ... welcomes his appointment to strengthen operations of their national physician ...
... ... , ... (PRWEB) March 11, 2010 -- ClearTrial, the leading provider of Clinical Trial Operations (CTO) ... Deutsche Bank and Cowen & Company at CBI,s 2010 Accounting and Reporting Congress in ...
Cached Biology Technology:FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 2Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 3Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman 4ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress 2ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress 3
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Biology Products: